VivoSeq
Other

Impairment

0

Pipeline Programs↗

6

Active Trials↗

15

Companies Involved↗

Impairment is an early-stage landscape with 0 programs across 15 companies. The most active players are Eli Lilly, Bristol-Myers Squibb, Bayer.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalC

Cumberland Pharmaceuticals

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalChiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

52

clinical trials

Completed34 · 65%
Unknown status7 · 13%
Recruiting5 · 10%
Terminated3 · 6%
Withdrawn2 · 4%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

52 trials

A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07165002·32 enrolled
Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment
Recruiting·JJohns Hopkins University·Phase 1·NCT06293040·90 enrolled
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Recruiting·Rhythm Pharmaceuticals logoRhythm Pharmaceuticals·Phase 1/2·NCT06239116·150 enrolled
Voiceitt for People With Impairments in Speech
Recruiting·UUniversity of Pittsburgh·Preclinical·NCT06874322·20 enrolled
Clinical Evaluation of Frequency Allocation for Bimodal CI Users
Recruiting·NNYU Langone Health·Preclinical·NCT06663917·13 enrolled
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT): Open Label
Not yet recruiting·MMedical University of South Carolina·Phase 2·NCT07689773·60 enrolled
Differences in Cannabis Impairment and Its Measurement Due to Route of Administration
Completed·JJohns Hopkins University·Phase 1·NCT03122691·23 enrolled
Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT04933747·26 enrolled
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
Completed·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 1·NCT05373953·44 enrolled
Non-intrusive Detection of Temporary Neurologic Impairment by Opioids
Completed·ZZxerex Corporation·N/A·NCT05489601·17 enrolled
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01836185·32 enrolled
The Impact of Oral Cannabis Administration and Co-Administration of Alcohol on Impairment
Completed·JJohns Hopkins University·Phase 1·NCT04931095·60 enrolled
Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects
Completed·Lundbeck logoLundbeck·Phase 1·NCT03189615·24 enrolled
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
Completed·Bayer logoBayer·Phase 3·NCT01331681·406 enrolled
To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects
Completed·Sunshine Lake Pharma Co., Ltd. logoSunshine Lake Pharma Co., Ltd.·Phase 1·NCT04552808·16 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)